Administration of ANG II induces iron deposition and upregulation of TGF-β1 mRNA in the rat liver

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 288, Issue 4 57-4, 2005, Pages

  Ishizaka, Nobukazu ^a   Saito, Kan ^a   Noiri, Eisei ^a   Sata, Masataka ^a   Ikeda, Hitoshi ^a   Ohno, Akihiko ^b   Ando, Jiro ^a   Mori, Ichiro ^c   Ohno, Minoru ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Iron chelator; Iron metabolism; Oxidative stress; Profibrotic gene

Indexed keywords

ANGIOTENSIN; DEFEROXAMINE; FERRIC FERROCYANIDE; FERRITIN; HEME OXYGENASE 1; IRON; IRON CHELATE; LOSARTAN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; HEART MUSCLE FIBROSIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; IRON METABOLISM; KIDNEY FIBROSIS; LIVER CELL; LIVER FIBROSIS; LIVER HEMORRHAGE; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOTTING, NORTHERN; BLOTTING, WESTERN; FERRITINS; HEME OXYGENASE (DECYCLIZING); HOMEOSTASIS; INFUSIONS, INTRAVENOUS; IRON; IRON CHELATING AGENTS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 20144380931     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00281.2004     Document Type: Article

References (35)

1. Aizawa T, Ishizaka N, Taguchi J, Kimura S, Kurokawa K, and Ohno M. Balloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injured rat carotid artery. Biochem Biophys Res Commun 261; 302-307, 1999.
2. Aizawa T, Ishizaka N, Usui S, Ohashi N, Ohno M, and Nagai R. ANG II and catecholamines increase plasma levels of 8-epi-prostaglandin F(2alpha) with different pressor dependencies in rats. Hypertension 39: 149-154, 2002.
3. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, and Rippe RA. Prolonged infusion of ANG II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 285: G642-G651, 2003.
4. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, and Brenner DA. NADPH oxidase signal transduces ANG II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394, 2003.
5. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, and Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of ANG II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132-1144, 2003.
6. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, and Delafontaine P. ANG II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142: 1489-1496, 2001.
7. Britton RS and Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 41: 343-348, 1994.
8. Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, and Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci 27: 909-916, 1982.
9. DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, and Kanel GC. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 29: 1779-1791, 1999.
10. Dijkstra CD, Dopp EA, Joling P, and Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54: 589-599, 1985.
11. Fletcher LM and Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 30: 131-136, 2003.
12. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers QT, Taylor WR, Harrison DG, de Leon H, Wilcox JN, and Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
13. Ishizaka N, Aizawa T, Mori I, Taguchi J, Yazaki Y, Nagai R, and Ohno M. Heme oxygenase-1 is upregulated in the rat heart in response to chronic administration of ANG II. Am J Physiol Heart Circ Physiol 279: H672-H678, 2000.
14. Ishizaka N, Aizawa T, Yamazaki I, Usui S, Mori I, Kurokawa K, Tang SS, Ingelfinger JR, Ohno M, and Nagai R. Abnormal iron deposition in renal cells in the rat with chronic ANG II administration. Lab Invest 82: 87-96, 2002.
15. Ishizaka N, de Leon H, Laursen JB, Fukui T, Wilcox JN, De Keulenaer G, Griendling KK, and Alexander RW. ANG II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation 96: 1923-1929, 1997.
16. Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, Usui S, Mori I, Ohno M, and Nagai R. Iron overload augments ANG II-induced cardiac fibrosis and promotes neointima formation. Circulation 106: 1840-1846, 2002.
17. Khan MF, Wu X, Tipnis UR, Ansari GA, and Boor PJ. Protein adducts of malondialdehyde and 4-hydroxynonenal in livers of iron-loaded rats: quantitation and localization. Toxicology 173: 193-201, 2002.
18. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, and Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 11: 851-857, 1997.
19. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, and Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 116: 61-69, 2003.
20. Luckey SW and Petersen DR. Metabolism of 4-hydroxynonenal by rat Kupffer cells. Arch Biochem Biophys 389: 77-83, 2001.
21. Metwally MA, Zein CO, and Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 99: 286-291, 2004.
22. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, Nagasaka T, Iwase M, Yamada Y, Nakashima N, and Yokota M. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 40: 168-174, 2002.
23. Otterbein L, Chin BY, Otterbein SL, Lowe VC, Fessler HE, and Choi AM. Mechanism of hemoglobin-induced protection against endotoxemia in rats: a ferritin-independent pathway. Am J Physiol Lung Cell Mol Physiol 272: L268-L275, 1997.
24. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, and Angus PW. Effect of ANG II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35: 376-385, 2001.
25. Parola M, Robino G, Marra F, Pinzani M, Bellomo G, Leonarduzzi G, Chiarugi P, Camandola S, Poli G, Waeg G, Gentilini P, and Dianzani MU. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest 102: 1942-1950, 1998.
26. Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, Mariani R, and Mancia G. Increased serum ferritin is common in men with essential hypertension. J Hypertens 20: 1513-1518, 2002.
27. Saito K, Ishizaka N, Mitani H, Ohno M, and Nagai R. Iron chelation and a free radical scavenger suppress ANG II-induced downregulation of klotho, an anti-aging gene, in rat. FEBS Lett 551: 58-62, 2003.
28. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, and Sakuta S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36: 1022, 2002.
29. Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, and Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 96: 620-630, 1995.
30. Tuncer I, Ozbek H, Ugras S, and Bayram I. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 55: 159-166, 2003.
31. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, and Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 124: 318-326, 2003.
32. Unchern S, Laoharuangpanya N, Phumala N, Sipankapracha P, Pootrakul P, Fucharoen S, Wanachivanawin W, and Chantharaksri U. The effects of vitamin E on platelet activity in beta-thalassaemia patients. Br J Haematol 123: 738-744, 2003.
33. Yamada T, Kuno A, Masuda K, Ogawa K, Sogawa M, Nakamura S, Ando T, Sano H, Nakazawa T, Ohara H, Nomura T, Joh T, and Itoh M. Candesartan, an ANG II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J Pharmacol Exp Ther 307: 17-23, 2003.
34. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, and Nakamura K. Therapeutic efficacy of an ANG II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40: 1222-1225, 2004.
35. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, and Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001.